

Supplemental Online Content

Mateo-Urdiales A, Sacco C, Petrone D, et al; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Estimated effectiveness of a primary cycle of protein recombinant vaccine NVX-CoV2373 against COVID-19. *JAMA Netw Open*. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854

eTable 1. Vaccine Effectiveness Against Notified SARS-CoV-2 Infection and Symptomatic COVID-19 in Those Starting the Primary Cycle With Novavax (NVX-CoV2373) From February 28 to September 4, 2022, Italy

eTable 2. Vaccine Effectiveness Against Notified SARS-CoV-2 Infection and Symptomatic COVID-19 for Novavax (NVX-CoV2373) According to Time From Full Vaccination (≥ 15 Days From Second Dose)

Results from sensitivity analysis where the reference period is days 0-14 post first dose administration.

eTable 1. Vaccine Effectiveness Against Notified SARS-CoV-2 Infection and Symptomatic COVID-19 in Those Starting the Primary Cycle With Novavax (NVX-CoV2373) From February 28 to September 4, 2022, Italy

| Outcome | Vaccination status | Person-days | Events | Crude rate (per 100 000 person-days) | VE (95% CI) |
|------------------------------|---------------------------|-------------|--------|---|---------------|
| All infections | 0-14 days post first dose | 310,650 | 622 | 200.2 | Reference |
| | Partial vaccination* | 510,152 | 1,001 | 196.2 | 8% (-3%-17%) |
| | Full vaccination** | 1,908,025 | 2,811 | 147.3 | 17% (8%-25%) |
| Symptomatic infection | 0-14 days post first dose | 310,650 | 225 | 72.4 | Reference |
| | Partial vaccination* | 510,152 | 360 | 70.6 | 12% (-4%-26%) |
| | Full vaccination** | 1,908,025 | 873 | 45.8 | 35% (25%-44%) |
| Hospitalisation | 0-14 days post first dose | 310,650 | 3 | 1.0 | - |
| | Partial vaccination* | 510,152 | 7 | 1.4 | - |
| | Full vaccination** | 1,908,025 | 18 | 0.9 | - |

IRR = Incidence Rate Ratio.
 VE = Vaccine Effectiveness.
 *15 days post first dose to 14 days post second dose
 **15+ days post second dose

eTable 2. Vaccine Effectiveness Against Notified SARS-CoV-2 Infection and Symptomatic COVID-19 for Novavax (NVX-CoV2373) According to Time From Full Vaccination (≥ 15 Days From Second Dose)

| Outcome | Vaccination status | Person-days | Events | Crude rate (per 100 000 person-days) | VE (95% CI) |
|------------------------|------------------------------|-------------|--------|---|---------------|
| All infections | 0-14 days post first dose | 310,650 | 622 | 200.2 | Reference |
| | Full vaccination 0-29 days | 504,653 | 602 | 119.3 | 29% (17%-39%) |
| | Full vaccination 30-59 days | 488,225 | 459 | 94.0 | 26% (12%-38%) |
| | Full vaccination 60-89 days | 467,672 | 983 | 210.2 | 5% (-15%-22%) |
| | Full vaccination 90-120 days | 447,475 | 767 | 171.4 | 14% (-8%-31%) |
| Symptomatic infections | 0-14 days post first dose | 310,650 | 225 | 72.4 | Reference |
| | Full vaccination 0-29 days | 504,653 | 220 | 43.6 | 34% (23%-43%) |
| | Full vaccination 30-59 days | 488,225 | 146 | 29.9 | 39% (28%-49%) |
| | Full vaccination 60-89 days | 467,672 | 296 | 63.3 | 28% (13%-40%) |
| | Full vaccination 90-120 days | 447,475 | 211 | 47.2 | 42% (28%-54%) |